Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 2, 2006 - Issue 4
Submit an article Journal homepage
61
Views
7
CrossRef citations to date
0
Altmetric
Review

Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease

Lei Zhao Cordis Corp., a Johnson & Johnson company, 7 Powder Horn Drive, Warren, NJ 07059, USA. [email protected]
,
Tilo Grosser The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, 421 Curie Blvd, Philadelphia, PA 19104, USA. [email protected]
,
Susanne Fries The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, 421 Curie Blvd, Philadelphia, PA 19104, USA. [email protected]
,
Leena Kadakia Cordis Corp., a Johnson & Johnson company, 7 Powder Horn Drive, Warren, NJ 07059, USA. [email protected]
,
He Wang University of Michigan Medical School, Department of Pathology, 1301 Catherine, Ann Arbor, MI 48109, USA. [email protected]
,
Jonathan Zhao Cordis Corp., a Johnson & Johnson company, 7 Powder Horn Drive, Warren, NJ 07059, USA. [email protected]
&
Robert Falotico Cordis Corp., a Johnson & Johnson company, 7 Powder Horn Drive, Warren, NJ 07059, USA. [email protected]
 show all
Pages 649-658 | Published online: 10 Jan 2014

References

  • Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science294(5548), 1871–1875 (2001).
  • Brash A. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem.274(34), 23679–23682 (1999).
  • FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov.2(11), 879–890 (2003).
  • Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta.1304(1), 65–84 (1996).
  • Yamamoto S. “Enzymatic” lipid peroxidation: reactions of mammalian lipoxygenases. Free Radic. Biol. Med.10(2), 149–159 (1991).
  • Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science220(4597), 568–575 (1983).
  • Kramer RM, Sharp JD. Structure, function and regulation of Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). FEBS Lett.410(1), 49–53 (1997).
  • Lin LL, Wartmann M, Lin AY et al. cPLA2 is phosphorylated and activated by MAP kinase. Cell72(2), 269–278 (1993).
  • Nicotra A, Lupo G, Giurdanella G. MAPKs mediate the activation of cytosolic phospholipase A2 by amyloid β (25–35) peptide in bovine retina pericytes. Biochim. Biophys. Acta.1733(2–3), 172–186 (2005).
  • Yokomizo T, Izumi T, Chang K et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature387, 620–624 (1997).
  • Yokomizo T, Kato K, Terawaki K et al. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med.192, 421–432 (2000).
  • Heise CE, O'Dowd BF, Figueroa DJ et al. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem.275, 30531–30536 (2000).
  • Lynch KR, O'Neill GP, Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature399, 789–793 (1999).
  • Hui Y, Yang G, Galczenski H et al. The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. J. Biol. Chem.276(50), 47489–47495 (2001).
  • Goodarzi K, Goodarzi M, Tager AM et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat. Immunol.4, 965–973 (2003).
  • Ott VL, Cambier JC, Kappler J et al. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol.4, 974–981 (2003).
  • Tager AM, Bromley SK, Medoff BD et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol.4, 982–990 (2003).
  • Yang G, Haczku A, Chen H et al. Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am. J. Physiol. Lung. Cell Mol. Physiol.286(5), L992–L1001 (2004).
  • Hui Y, Cheng Y, Smalera I et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation110(21), 3360–3366 (2004).
  • Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem.69, 145–182 (2000).
  • Malkowski MG, Ginell SL, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science289, 1933–1937 (2000).
  • Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res.42(5), 377–404 (2003).
  • Grosser T, Fries F, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest.116(1), 4–15 (2006).
  • Patrono C, Garcia Rodriguez LA, Landolfi R et al. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med.353(22), 2373–2383 (2005).
  • FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med.345(6), 433–442 (2001).
  • Topper JN, Cai J, Falb D et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl Acad. Sci. USA93, 10417–10422 (1996).
  • Grosser T, Yusuff S, Cheskis E et al. Developmental expression of functional cyclooxygenases in zebrafish. Proc. Natl Acad. Sci. USA99, 8418–8423 (2002).
  • Matsuoka T, Hirata M, Tanaka H et al. Prostaglandin D2 as a mediator of allergic asthma. Science287, 2013–2017 (2000).
  • Hirai H, Tanaka K, Yoshie O et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med.193, 255–261 (2001).
  • Ushikubi F, Segi E, Sugimoto Y et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature395, 281–284 (1998).
  • Namba T, Oida H, Sugimoto Y et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J. Biol. Chem.269(13), 9986–9992 (1994).
  • Raychowdhury MK, Yukawa M, Collins LJ et al. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J. Biol. Chem.269, 19256–19261 (1994).
  • Abramovitz M, Boie Y, Nguyen T. Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem.269(4), 2632–2636 (1994).
  • Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340(2), 115–126 (1999).
  • Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell104(4), 503–516 (2001).
  • Libby P. Inflammation in atherosclerosis. Nature420(6917), 868–874 (2002).
  • Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation105(9), 1135–1143 (2002).
  • Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med.8(11), 1211–1217 (2002).
  • Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med.14(5), 191–195 (2004).
  • Funk CD, Cyrus T. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc. Med.11(3–4), 116–124 (2001).
  • Yla-Herttuala S, Rosenfeld ME, Parthasarathy S et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl Acad. Sci. USA87(18), 6959–6963 (1990).
  • Yla-Herttuala S, Rosenfeld ME, Parthasarathy S et al. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Invest.87(4), 1146–1152 (1991).
  • Kuhn H, Heydeck D, Hugou I et al.In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J. Clin. Invest.99(5), 888–893 (1997).
  • Rydberg EK, Krettek A, Ullstrom C. Hypoxia increases LDL oxidation and expression of 15-lipoxygenase-2 in human macrophages. Arterioscler. Thromb. Vasc. Biol.24(11), 2040–2045 (2004).
  • Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA100(3), 1238–1243 (2003).
  • Cyrus T, Witztum JL, Rader DJ et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest.103(11), 1597–1604 (1999).
  • Cyrus T, Pratico D, Zhao L et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation103(18), 2277–2282 (2001).
  • George J, Afek A, Shaish A et al. 12/15-lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation104(14), 1646–1650 (2001).
  • Zhao L, Cuff CA, Moss E et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J. Biol. Chem.277(38), 35350–35356 (2002).
  • Zhao L, Pratico D, Rader DJ et al. 12/15-Lipoxygenase gene disruption and Vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat.78(1–4), 185–193 (2005).
  • Huo Y, Zhao L, Hyman MC et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation110(14), 2024–2031 (2004).
  • Reilly KB, Srinivasan S, Hatley ME et al. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J. Biol. Chem.279(10), 9440–9450 (2004).
  • Harats D, Shaish A, George J et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol.20(9), 2100–2105 (2000).
  • Cai Q, Lanting L, Natarajan R. Interaction of monocytes with vascular smooth muscle cells regulates monocyte survival and differentiation through distinct pathways. Arterioscler. Thromb. Vasc. Biol.24, 2263–2270 (2004).
  • Cai Q, Lanting L, Natarajan R. Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. Am. J. Physiol. Cell Physiol.287, C707–C714 (2004).
  • Hatley ME, Srinivasan S, Reilly KB et al. Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J. Biol. Chem.278(28), 25369–25375 (2003).
  • Bolick DT, Orr AW, Whetzel A et al. 12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-κB. Arterioscler. Thromb. Vasc. Biol.25(11), 2301–2307 (2005).
  • Natarajan R, Gerrity RG, Gu JL et al. Role of 12-lipoxygenase and oxidant stress in hyperglycaemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia45(1), 125–133 (2002).
  • Natarajan R, Pei H, Gu JL et al. Evidence for 12-lipoxygenase induction in the vessel wall following balloon injury. Cardiovasc. Res.41(2), 489–499 (1999).
  • Gu JL, Pei H, Thomas L et al. Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation103(10), 1446–1452 (2001).
  • Sendobry SM, Cornicelli JA, Welch K et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol.120(7), 1199–1206 (1997).
  • Bocan TM, Rosebury WS, Mueller SB et al. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis136(2), 203–216 (1998).
  • Shen J, Herderick E, Cornhill JF et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest.98(10), 2201–2208 (1996).
  • Mehrabian M, Wong J, Wang X et al. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ. Res.89(2), 125–130 (2001).
  • Welch CL, Bretschger S, Latib N et al. Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. Proc. Natl Acad. Sci. USA98(14), 7946–7951 (2001).
  • Mehrabian M, Allayee H, Wong J et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res.91(2), 120–126 (2002).
  • Zhao L, Moos MP, Grabner R et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med.10(9), 966–973 (2004).
  • Subbarao K, Jala VR, Mathis S et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol.24(2), 369–375 (2004).
  • Aiello RJ, Bourassa PA, Lindsey S et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol.22(3), 443–449 (2002).
  • Heller EA, Liu E, Tager AM et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation112(4), 578–586 (2005).
  • Yajima N, Masuda M, Miyazaki M et al. Oxidative stress is involved in the development of experimental abdominal aortic aneurysm: a study of the transcription profile with complementary DNA microarray. J. Vasc. Surg.36(2), 379–385 (2002).
  • De Caterina R, Mazzone A, Giannessi D et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta.47(10–11), S182–S185 (1988).
  • Patrignani P, Daffonchio L, Hernandez A et al. Release of contracting autacoids by aortae of normal and atherosclerotic rabbits. J. Cardiovasc. Pharmacol.20(S12), S208–S210 (1992).
  • Dwyer JH, Allayee H, Dwyer KM et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med.350(1), 29–37 (2004).
  • Mehrabian M, Allayee H, Stockton J et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat. Genet.37(11), 1224–1233 (2005).
  • Helgadottir A, Manolescu A, Thorleifsson G et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet.36(3), 233–239 (2004).
  • Helgadottir A, Gretarsdottir S, St Clair D et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet.76(3), 505–509 (2005).
  • Lohmussaar E, Gschwendtner A, Mueller JC et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke36(4), 731–736 (2005).
  • Kedda MA, Worsley P, Shi J et al. Polymorphisms in the 5-lipoxygenase activating protein (ALOX5AP) gene are not associated with asthma in an Australian population. Clin. Exp. Allergy.35(3), 332–338 (2005).
  • Kajimoto K, Shioji K, Ishida C et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ. J.69(9), 1029–1034 (2005).
  • Meschia JF, Brott TG, Brown RD Jr et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann. Neurol.58(3), 351–361 (2005).
  • Cipollone F, Mezzetti A, Fazia ML et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol.25(8), 1665–1670 (2005).
  • Hakonarson H, Thorvaldsson S, Helgadottir A et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA293(18), 2245–2256 (2005).
  • Pratico D, Cyrus T, Zhang ZB et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl Acad. Sci. USA98(6), 3358–3363 (2001).
  • Belton OA, Duffy A, Toomey S et al. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation108(24), 3017–3023 (2003).
  • Egan KM, Wang M, Fries S et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation111(3), 334–342 (2005).
  • Kobayashi T, Tahara Y, Matsumoto M et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest.114(6), 784–794 (2004).
  • Worth NF, Berry CL, Thomas AC et al. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis183(1), 65–73 (2005).
  • Cheng Y, Austin SC, Rocca B et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science296(5567), 539–541 (2002).
  • Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell83(3), 473–482 (1995).
  • Loftin CD, Trivedi DB, Tiano HF et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl Acad. Sci. USA98(3), 1059–1064 (2001).
  • Grosser T, Fries S, FitzGerald GA. Cycloxygenase inhibition and blood pressure regulation. In: Advanced Therapy in Hypertension and Vascular Disease. Mohler ER, Townsend RR (Eds), B.C. Decker Hamilton, Ontario, Canada, 492–501 (2006).
  • Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation105(15), 1816–1823 (2002).
  • Burleigh ME, Babaev VR, Yancey PG et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J. Mol. Cell. Cardiol.39(3), 443–452 (2005).
  • Rott D, Zhu J, Burnett MS et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. Coll. Cardiol.41(10), 1812–1819 (2003).
  • Olesen M, Kwong E, Meztli A et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand. Cardiovasc. J.36(6), 362–367 (2002).
  • Egan KM, Lawson JA, Fries S et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science306(5703), 1954–1957 (2004).
  • Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352, 1092–1102 (2005).
  • Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352, 1071–1080 (2005).
  • Kipshidze N, Leon MB, Tsapenko M et al. Update on sirolimus drug-eluting stents. Curr Pharm Des.10(4), 337–348 (2004).
  • Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346(23), 1773–1780 (2002).
  • Ong AT, Serruys PW. Technology insight: an overview of research in drug-eluting stents. Nat. Clin. Pract. Cardiovasc. Med.2(12), 647–658 (2005).
  • Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation111(17), 2257–2273 (2005).
  • Moses JW, Leon MB, Popma JJ et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349(14), 1315–1323 (2003).
  • Attur MG, Patel R, Thakker G et al. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporine, rapamycin, and FK-506 on inducible nitrix oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm. Res.49(1), 20–26 (2000).
  • Hocherl K, Hensel C, Ulbricht B et al. Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney. Br. J. Pharmacol.145(8), 1112–1122 (2005).
  • Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation106(1), 136–140 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.